{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:57:33Z","timestamp":1787669853910,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Fluorescence in situ hybridization (FISH) for plasma cell neoplasms (PCNs) requires plasma cell (PC) identification or purification strategies to optimize results. We compared the efficacy of cytoplasmic immunoglobulin FISH (cIg-FISH) and fluorescence-activated cell sorting FISH (FACS-FISH) in a clinical laboratory setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The FISH analysis results of 14,855 samples from individuals with a suspected PCN subjected to cytogenetic evaluation between 2019 and 2022 with cIg-FISH (n = 6917) or FACS-FISH (n = 7938) testing were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fluorescence-activated cell sorting\u2013FISH increased the detection rate of abnormalities in comparison with cIg-FISH, with abnormal results documented in 54% vs 50% of cases, respectively (P &amp;lt; .001). It improved the detection of IGH::CCND1 (P &amp;lt; .001), IGH::MAF (P &amp;lt; .001), IGH::MAFB (P &amp;lt; .001), other IGH rearrangements (P &amp;lt; .001), and gains\/amplifications of 1q (P &amp;lt; .001), whereas the detection rates of IGH::FGFR3 fusions (P = .3), loss of 17p (P = .3), and other abnormalities, including hyperdiploidy (P = .5), were similar. Insufficient PC yield for FISH analysis was decreased between cIg-FISH and FACS-FISH (22% and 3% respectively, P &amp;lt; .001). Flow cytometry allowed establishment of ploidy status in 91% of cases. In addition, FACS-FISH decreased analysis times, workload efforts, and operating costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Fluorescence-activated cell sorting\u2013FISH is an efficient PC purification strategy that affords significant improvement in diagnostic yield and decreases workflow requirements in comparison with cIg-FISH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad108","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T11:39:20Z","timestamp":1693654760000},"page":"60-70","source":"Crossref","is-referenced-by-count":11,"title":["Superior detection rate of plasma cell FISH using FACS-FISH"],"prefix":"10.1093","volume":"161","author":[{"given":"Marie-France","family":"Gagnon","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally M","family":"Midthun","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Fangel","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M","family":"Schuh","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy M","family":"Luoma","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E","family":"Pearce","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid G","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic , Jacksonville, FL , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano J","family":"Arribas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Mayo Clinic , Scottsdale, AZ , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Mayo Clinic , Scottsdale, AZ , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Mayo Clinic , Scottsdale, AZ , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya","family":"Zepeda-Mendoza","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"},{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"},{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T","family":"Greipp","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"},{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M","family":"Timm","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E","family":"Otteson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4293","authenticated-orcid":false,"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-4485","authenticated-orcid":false,"given":"Horatiu","family":"Olteanu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess F","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"},{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"},{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Mayo Clinic , Jacksonville, FL , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda B","family":"Baughn","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic , Rochester, MN , US"},{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic , Rochester, MN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"key":"2024010408032730600_CIT0001","first-page":"2210","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume-title":"Leukemia.","author":"Fonseca","year":"2009"},{"key":"2024010408032730600_CIT0002","first-page":"2889","article-title":"How I treat high-risk multiple myeloma","volume-title":"Blood.","author":"Zamagni","year":"2022"},{"key":"2024010408032730600_CIT0003","first-page":"2955","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume-title":"Blood.","author":"Sonneveld","year":"2016"},{"key":"2024010408032730600_CIT0004","first-page":"1095","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume-title":"Mayo Clin Proc.","author":"Kumar","year":"2009"},{"key":"2024010408032730600_CIT0005","first-page":"2863","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume-title":"J Clin Oncol.","author":"Palumbo","year":"2015"},{"key":"2024010408032730600_CIT0006","first-page":"360","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume-title":"Mayo Clin Proc.","author":"Mikhael","year":"2013"},{"key":"2024010408032730600_CIT0007","first-page":"157","article-title":"The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells","volume-title":"Int J Lab Hematol.","author":"Panakkal","year":"2022"},{"key":"2024010408032730600_CIT0008","first-page":"1272","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume-title":"Haematologica.","author":"Ross","year":"2012"},{"key":"2024010408032730600_CIT0009","first-page":"184","article-title":"Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: an evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders","volume-title":"Cancer Genet","author":"Pugh","year":"2018"},{"key":"2024010408032730600_CIT0010","first-page":"712","article-title":"Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques","volume-title":"Am J Clin Pathol.","author":"Hartmann","year":"2011"},{"key":"2024010408032730600_CIT0011","first-page":"991","article-title":"Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia","volume-title":"Genes Chromosomes Cancer.","author":"Put","year":"2010"},{"key":"2024010408032730600_CIT0012","first-page":"667","article-title":"Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization","volume-title":"Genet Med.","author":"Mascarello","year":"2011"},{"key":"2024010408032730600_CIT0013","first-page":"2043","article-title":"Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders","volume-title":"Leukemia.","author":"Morice","year":"2007"},{"key":"2024010408032730600_CIT0014","first-page":"704","article-title":"Chromosomal abnormalities in systemic amyloidosis","volume-title":"Br J Haematol.","author":"Fonseca","year":"1998"},{"key":"2024010408032730600_CIT0015","first-page":"103","article-title":"Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma","volume-title":"Blood Cancer J.","author":"Smadbeck","year":"2019"},{"key":"2024010408032730600_CIT0016","first-page":"424","article-title":"Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method","volume-title":"Am J Hematol.","author":"Sidana","year":"2019"},{"key":"2024010408032730600_CIT0017","first-page":"E117","article-title":"Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma","volume-title":"Am J Hematol.","author":"Sidana","year":"2019"},{"key":"2024010408032730600_CIT0018","first-page":"6581","article-title":"Implications of MYC rearrangements in newly diagnosed multiple myeloma","volume-title":"Clin Cancer Res.","author":"Abdallah","year":"2020"},{"key":"2024010408032730600_CIT0019","first-page":"e600","article-title":"Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma","volume-title":"Blood Cancer J.","author":"Binder","year":"2017"},{"key":"2024010408032730600_CIT0020","first-page":"1676","article-title":"CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance","volume-title":"Front Immunol.","author":"Seckinger","year":"2018"},{"key":"2024010408032730600_CIT0021","first-page":"1546","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume-title":"Cancer Res.","author":"Fonseca","year":"2004"},{"key":"2024010408032730600_CIT0022","first-page":"228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume-title":"Proc Natl Acad Sci U S A.","author":"Shou","year":"2000"},{"key":"2024010408032730600_CIT0023","first-page":"2032","article-title":"t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma","volume-title":"Leukemia.","author":"Garand","year":"2003"},{"key":"2024010408032730600_CIT0024","first-page":"8287","article-title":"Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma","volume-title":"Sci Rep.","author":"Ha","year":"2022"},{"issue":"4","key":"2024010408032730600_CIT0025","first-page":"226","article-title":"Application of FICTION technique to the detection of genetic aberrations in multiple myeloma [in Chinese]","volume":"32","author":"Wang","year":"2011","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2024010408032730600_CIT0026","first-page":"196","article-title":"Clinical utility of a diagnostic approach to detect genetic abnormalities in multiple myeloma: a single institution experience","volume-title":"Ann Lab Med","author":"Jung","year":"2018"},{"key":"2024010408032730600_CIT0027","first-page":"5430","article-title":"The prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma","volume-title":"Clin Cancer Res.","author":"Sharma","year":"2021"},{"key":"2024010408032730600_CIT0028","first-page":"625","article-title":"Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms","volume-title":"Arch Pathol Lab Med.","author":"Lu","year":"2013"},{"key":"2024010408032730600_CIT0029","first-page":"666","article-title":"Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility","volume-title":"Cancer Epidemiol Biomarkers Prev.","author":"Ahmann","year":"2008"},{"key":"2024010408032730600_CIT0030","first-page":"497","article-title":"CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab","volume-title":"Cytometry B Clin Cytom.","author":"Soh","year":"2021"},{"issue":"5","key":"2024010408032730600_CIT0031","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol."},{"issue":"6, pt 1","key":"2024010408032730600_CIT0032","first-page":"e190","article-title":"Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma","volume":"32","author":"Reid","year":"2010","journal-title":"Int J Lab Hematol."},{"key":"2024010408032730600_CIT0033","first-page":"e328","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume-title":"Lancet Oncol.","author":"Kumar","year":"2016"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/161\/1\/60\/54917820\/aqad108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/161\/1\/60\/54917820\/aqad108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T08:05:30Z","timestamp":1704355530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/161\/1\/60\/7258898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,2]]},"published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad108","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,9,2]]}}}